Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
Liver-Specific Ligands
Tissue
n/a nM (reported value)
Selection Buffer (PBS, 1 M NaCl, and 2% Triton X-100) Wash Buffers (0.1% Sodium Borohydride, 0.1 M Phosphate Buffer) (PBS, 5% BSA, 0.1% cold water fish gelatin, and 5% normal goat serum in PBS) Incubation Buffer (PBS and 1.1% BSA-C)
N/A°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
77% liver uptake
Liver-Specific Ligands (236) (ID# 200)
NH2GlnArgValLeuValLysLysCOOCOOH
7
916.24 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Ludtke et al. "In Vivo Selection and Validation of Liver-Specific Ligands Using a New T7 Phage Peptide Display System." Drug Delivery, 14(2007): 357-369.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.